WO2009052942A3 - Stabilisierung von hydrophoben proteintherapeutika - Google Patents

Stabilisierung von hydrophoben proteintherapeutika Download PDF

Info

Publication number
WO2009052942A3
WO2009052942A3 PCT/EP2008/008450 EP2008008450W WO2009052942A3 WO 2009052942 A3 WO2009052942 A3 WO 2009052942A3 EP 2008008450 W EP2008008450 W EP 2008008450W WO 2009052942 A3 WO2009052942 A3 WO 2009052942A3
Authority
WO
WIPO (PCT)
Prior art keywords
stabilization
therapeutic agents
hydrophobic protein
protein therapeutic
hydrophobic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/008450
Other languages
English (en)
French (fr)
Other versions
WO2009052942A2 (de
Inventor
Bernd Otto
Florian Battermann
Ruediger Kohl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER
STIFTUNG TIERAERZTLICHE HOCHSC
Original Assignee
STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER
STIFTUNG TIERAERZTLICHE HOCHSC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER, STIFTUNG TIERAERZTLICHE HOCHSC filed Critical STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER
Priority to US12/738,818 priority Critical patent/US20110086003A1/en
Priority to EP08802806A priority patent/EP2217277A2/de
Publication of WO2009052942A2 publication Critical patent/WO2009052942A2/de
Publication of WO2009052942A3 publication Critical patent/WO2009052942A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Die vorliegende Erfindung betrifft eine stabilisierte Lösung umfassend ein hydrophobes Protein, ein Verfahren zu dessen Herstellung sowie die stabilisierte Lösung als Arzneimittel und dessen Verwendung.
PCT/EP2008/008450 2007-10-19 2008-10-07 Stabilisierung von hydrophoben proteintherapeutika Ceased WO2009052942A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/738,818 US20110086003A1 (en) 2007-10-19 2008-10-07 Stabilization of hydrophobic protein therapeutic agents
EP08802806A EP2217277A2 (de) 2007-10-19 2008-10-07 Stabilisierung von hydrophoben proteintherapeutika

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007050165.1 2007-10-19
DE102007050165A DE102007050165B4 (de) 2007-10-19 2007-10-19 Stabilisierte Lösung, Verfahren zu deren Herstellung sowie deren Verwendung und Arzneimittel in Form einer stabilisierten Lösung

Publications (2)

Publication Number Publication Date
WO2009052942A2 WO2009052942A2 (de) 2009-04-30
WO2009052942A3 true WO2009052942A3 (de) 2009-07-09

Family

ID=40435812

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008450 Ceased WO2009052942A2 (de) 2007-10-19 2008-10-07 Stabilisierung von hydrophoben proteintherapeutika

Country Status (4)

Country Link
US (1) US20110086003A1 (de)
EP (1) EP2217277A2 (de)
DE (1) DE102007050165B4 (de)
WO (1) WO2009052942A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009032179A1 (de) * 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
KR20140093603A (ko) * 2010-12-30 2014-07-28 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 병원체 불활성화제로서의 글리콜
CN105310988B (zh) * 2015-11-23 2018-05-04 哈药集团生物工程有限公司 一种含有重组人干扰素α2b的冻干药物组合物
CN112294760B (zh) * 2019-07-26 2025-12-12 宁波新致生物科技有限公司 一种液体制剂及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0080879A2 (de) * 1981-11-28 1983-06-08 Sunstar Kabushiki Kaisha Stabilisiertes Interferon enthaltende pharmazeutische Zusammensetzung
WO1989004177A1 (en) * 1987-11-03 1989-05-18 Genentech, Inc. Gamma interferon formulation
WO2003066102A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte zubereitung enthaltend immuncytokine
US20030229047A1 (en) * 2002-06-05 2003-12-11 Rajashree Joshi-Hangal Liquid formulation of decitabine and use of the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA83768B (en) * 1982-03-01 1983-10-26 Hoffmann La Roche Homogeneous human immune interferon and process therefor
JPS5925333A (ja) * 1982-08-03 1984-02-09 Toray Ind Inc 糖鎖を持たないインタ−フエロン−βの安定化方法
IL117948A0 (en) * 1995-04-18 1996-08-04 Horiuchi Co Ltd Reusable cleaning solutions containing stabilized enzymes
CA2304808C (en) * 1997-09-23 2011-03-22 Michael Tschope Liquid interferon-.beta. formulations
BRPI0411114B8 (pt) * 2003-06-10 2021-05-25 Lg Chemical Ltd solução aquosa estável de eritropoetina humana, não contendo albumina de soro
KR100524872B1 (ko) * 2003-12-04 2005-11-01 씨제이 주식회사 인터페론 베타의 정제방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0080879A2 (de) * 1981-11-28 1983-06-08 Sunstar Kabushiki Kaisha Stabilisiertes Interferon enthaltende pharmazeutische Zusammensetzung
WO1989004177A1 (en) * 1987-11-03 1989-05-18 Genentech, Inc. Gamma interferon formulation
WO2003066102A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte zubereitung enthaltend immuncytokine
US20030229047A1 (en) * 2002-06-05 2003-12-11 Rajashree Joshi-Hangal Liquid formulation of decitabine and use of the same

Also Published As

Publication number Publication date
EP2217277A2 (de) 2010-08-18
US20110086003A1 (en) 2011-04-14
DE102007050165B4 (de) 2010-06-17
WO2009052942A2 (de) 2009-04-30
DE102007050165A1 (de) 2009-04-23

Similar Documents

Publication Publication Date Title
MX2010009222A (es) Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
WO2009145456A3 (ko) 헤테로사이클 유도체
PT1834635E (pt) Sistemas estáveis de nanocápsula para a administração de moléculas activas
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
WO2010096394A3 (en) Aldehyde-tagged protein-based drug carriers and methods of use
WO2008057550A3 (en) Stabilization of vaccines by lyophilization
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
WO2011006143A3 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases, such as e.g. malaria
WO2009012871A3 (de) Uv-filter-kapsel
MX2009003382A (es) Derivados de sulfonamidas sustituidos.
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
EP1937633B8 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
WO2012065102A3 (en) S-t-butyl protected cysteine di-peptide analogs and related compounds
WO2009023434A3 (en) Method for stabilizing phenylephrine
SI2024368T1 (sl) Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2011006935A3 (en) Tetrazole derivatives
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
WO2010102778A3 (de) Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
IL194961A0 (en) Compounds a-r-x for the manufacture of pharmaceutical preparations
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2008131946A3 (de) Substituierte amid-derivate
MX2009013708A (es) Uso de derivados de acido tetramico para combatir vectores transmisores de virus.
MX2009011999A (es) Extruidos con enmascaramiento del sabor mejorado.
WO2011051916A3 (en) Stabilized protein formulations and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08802806

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008802806

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12738818

Country of ref document: US